• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    • Home
    • Griffith Research Online
    • Conference outputs
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Ixekizumab improves patient-reported outcomes through 52 weeks in patients with active psoriatic arthritis and previous inadequate response to tumor necrosis factor-inhibitors

    Author(s)
    Kavanaugh, A
    Marzo-Ortega, H
    Vender, R
    Birt, J
    Adams, D
    Benichou, O
    Lin, C-Y
    Nash, P
    Griffith University Author(s)
    Nash, Peter
    Year published
    2018
    Metadata
    Show full item record
    Abstract
    Aim Up to 24 weeks, ixekizumab (IXE) was superior to placebo (PBO) in patients with active psoriatic arthritis (PsA) and inadequate response to TNF inhibitors (TNFi) (phase 3 trial; SPIRIT‐P2).1 We report Week 52 interim patient‐reported outcomes (PROs) of IXE, during the SPIRIT‐P2 Extension Period (EP). Methods During Double‐Blind Treatment Period (DBTP; Weeks 0‐24), 363 patients with inadequate response or intolerance to TNFi were randomized 1:1:1 to subcutaneous administration of either 80 mg IXE every 4 weeks (Q4W; N=122) or 2 weeks (Q2W; N=123) following a 160 mg starting dose, or PBO (N=118). On completion of DBTP, ...
    View more >
    Aim Up to 24 weeks, ixekizumab (IXE) was superior to placebo (PBO) in patients with active psoriatic arthritis (PsA) and inadequate response to TNF inhibitors (TNFi) (phase 3 trial; SPIRIT‐P2).1 We report Week 52 interim patient‐reported outcomes (PROs) of IXE, during the SPIRIT‐P2 Extension Period (EP). Methods During Double‐Blind Treatment Period (DBTP; Weeks 0‐24), 363 patients with inadequate response or intolerance to TNFi were randomized 1:1:1 to subcutaneous administration of either 80 mg IXE every 4 weeks (Q4W; N=122) or 2 weeks (Q2W; N=123) following a 160 mg starting dose, or PBO (N=118). On completion of DBTP, 310 patients entered EP (Weeks 24‐156). Patients in IXE arms continued the same dose regimen in EP. PBO patients were re‐randomized (1:1) to IXE Q4W or Q2W at Week 16 (inadequate responders) or Week 24 after a 160 mg starting dose. At baseline and week 52 in EP, descriptive statistics were used to summarize PROs: Short Form‐36 Health Survey (SF‐36) Physical Component Summary (PCS) and Mental Component Summary (MCS), European Quality of Life 5 Dimensions Visual Analog Scale (EQ‐5D VAS; 0‐100 scale), Work Productivity and Activity Impairment‐Specific Health Problem (WPAI‐SHP), fatigue Numeric Rating Scale (NRS; unvalidated), and the itch NRS (in patients with baseline psoriatic lesion ≥3% body surface area (BSA; N=175)). Results The EP population had impaired physical and mental function, QoL, and work productivity at baseline. Patients receiving IXE up to 52 weeks reported improvements in SF‐36 (PCS and MCS), EQ‐5D VAS, WPAI‐SHP (presenteeism, work‐productivity, and activity‐impairment), fatigue NRS and itch NRS. Conclusions In patients with active PsA and previous inadequate response to TNF‐i, IXE provided sustained improvement up to 52 weeks in all measured PROs, including physical and mental function, QoL, work productivity, fatigue, and itch (≥3% BSA psoriasis).
    View less >
    Conference Title
    Internal Medicine Journal
    Volume
    48
    Issue
    S4
    Publisher URI
    https://onlinelibrary.wiley.com/doi/10.1111/imj.13772
    Subject
    Cardiorespiratory Medicine and Haematology
    Clinical Sciences
    Public Health and Health Services
    Science & Technology
    Life Sciences & Biomedicine
    Medicine, General & Internal
    General & Internal Medicine
    Publication URI
    http://hdl.handle.net/10072/402501
    Collection
    • Conference outputs

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander